Washington, D.C. 20549

                            REPORT OF FOREIGN ISSUER

                      Pursuant to Rule 13a-16 or 15d-16 of
                       the Securities Exchange Act of 1934

                           For the month of March 2008

                              AETERNA ZENTARIS INC.
                        1405, boul. du Parc-Technologique
                                 Quebec, Quebec
                                 Canada, G1P 4P5
                    (Address of principal executive offices)

Indicate by check mark whether the registrant  files or will file annual reports
under cover of Form 20-F or Form 40-F.

                        Form 20-F / /        Form 40-F /X/

Indicate by check mark whether the  registrant  by  furnishing  the  information
contained  in this  Form is  also  thereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

                               Yes / /      No /X/

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-____

                                 DOCUMENTS INDEX

Documents    Description
---------    -------------------------------------------------------------------
1.           Press Release dated March 26, 2008: AEterna Zentaris Begins Second
             Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia

                                                         [AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada  G1P 4P5  T 418 652-8525  F 418 652-0881

                                                           PRESS RELEASE
                                                           For immediate release


QUEBEC CITY, CANADA, MARCH 26, 2008 - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX:
AEZ), a global biopharmaceutical company focused on endocrine therapy and
oncology, today reported dosing has commenced with its flagship product
candidate, cetrorelix, the Company's lead luteinizing hormone-releasing hormone
(LHRH) antagonist, in the second efficacy study of its Phase 3 program in benign
prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate.

"We are very pleased to be on track with our Phase 3 clinical program for
cetrorelix in BPH," said David J. Mazzo, Ph.D., President and CEO, AEterna
Zentaris. "Based on our new understanding of the multiple processes involved in
the development of BPH and its symptoms, cetrorelix may offer a novel
therapeutic approach to doctors and patients currently making trade-offs in
care. We look forward to continuing our investigation of cetrorelix in this
comprehensive clinical program."

patients, and will assess an intermittent dosage regimen of cetrorelix as a
potential safe and tolerable treatment providing prolonged improvement in
BPH-related signs and symptoms. This Phase 3 trial, conducted in Europe under
the supervision of lead investigator, Prof. Dr. Frans M.J. Debruyne, MD, of the
Andros Mannenkliniek, Arnhem, The Netherlands, is part of the Company's Phase 3
program with cetrorelix being studied in approximately 1,500 patients in North
America and Europe in men with symptomatic BPH.


The first multi-center efficacy study for which first patient randomization
commenced in April 2007, is currently being conducted primarily in the United
States and Canada, with additional sites in Europe and involves approximately
600 patients under the supervision of lead investigator, Herbert Lepor, MD,
Professor at NY University School of Medicine, New York. Patients enter a 4-week
run-in no-treatment observation period to confirm severity and stability of
voiding symptoms based on the International Prostate Symptom Score (IPSS).
Patients are then randomly allocated to cetrorelix or placebo in a double-blind
fashion. Patients are administered cetrorelix by intra-muscular (IM) injection
at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label
extension, patients will receive cetrorelix by IM injection at Week 52, 54, 78
and 80 will be followed up to Week 90.

The second multi-center Phase 3 efficacy study for which first patient dosing
was announced today, will enroll approximately 400 patients in Europe. Patients
in this randomized placebo-controlled study with open-label extension, will
receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is
absolute change in IPSS between baseline and Week 52. Other efficacy endpoints
include additional measures of BPH symptom progression and the need for
BPH-related surgery. Safety endpoints include changes in sexual function. Other
important endpoints include plasma changes in levels of testosterone, and
assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, expected to
commence shortly, is an open-label, single-armed study involving approximately
500 patients in both North America and Europe.


Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging
men - affecting more than 20 million men in the United States - but its etiology
is far from being completely understood. Data from ongoing research suggest BPH
and lower urinary tract symptoms (LUTS) are more complex conditions than once
thought. While previous research on BPH etiology tended to focus on testosterone
and other hormones, more recent research suggests other factors - including
inflammation, various growth factors, and adrenoreceptors - actually may play a
greater role in the development of BPH and LUTS.

BPH is associated with LUTS, including: frequent urination, a sudden,
uncontrollable urge to urinate, waking at night to urinate (nocturia),
difficulty starting a urine stream (hesitancy and straining), decreased strength
of the urine stream (weak flow), feeling that the bladder is not completely
empty, an urge to urinate again soon after urinating and pain during urination
(dysuria). Currently available therapies may improve symptoms to some degree,
but often come with sexual and other side effects.


Cetrorelix pamoate is an investigational agent that has shown in Phase 2 studies
to provide fast and long lasting relief of BPH symptoms and was well tolerated,
with a low incidence of sexual side effects. Cetrorelix is part of AEterna
Zentaris' LHRH antagonist therapeutic approach. This peptide-based active
substance was developed by the Company in cooperation with Nobel Prize winner
Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH
antagonist approved for therapeutic use as part of IN VITRO fertilization
programs (controlled ovulation stimulation/assisted reproductive technologies)
in Europe, the USA and Japan. It was launched on the market through Serono (now
Merck Serono) in the U.S., Europe and in several other countries, as well as in
Japan through Shionogi.

In addition to the Phase 3 program in BPH, cetrorelix is also being studied in a
Phase 2b program in this same indication in Japan, sponsored by the Company's
partner, Shionogi.



AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine
therapy and oncology, with proven expertise in drug discovery, development and

News releases and additional information are available at


This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of the Company
to take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein to reflect
future results, events or developments except if we are requested by a
governmental authority or applicable law.



Jenene Thomas
Senior Director, Investor Relations & Corporate Communications
(908) 626-5509

Paul Burroughs
Media Relations
(418) 652-8525 ext. 406



     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                  AETERNA ZENTARIS INC.

Date:  March 27, 2008             By: /s/Mario Paradis
---------------------                 ------------------------------------------
                                      Mario Paradis
                                      Senior Vice President, Administrative and
                                      Legal Affairs and Corporate Secretary